| Comprehensive Molecular Profiling of Lung Adenocarcinoma CGAR Network | 4577* | |
| A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2545 | 2017 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2421 | 2018 |
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing M Imielinski, AH Berger, PS Hammerman, B Hernandez, TJ Pugh, ... Cell 150 (6), 1107-1120, 2012 | 1980 | 2012 |
| Maturation of the immune response in germinal centers C Berek, A Berger, M Apel Cell 67 (6), 1121-1129, 1991 | 1232 | 1991 |
| Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas JD Campbell, A Alexandrov, J Kim, J Wala, AH Berger, CS Pedamallu, ... Nature genetics 48 (6), 607-616, 2016 | 1112 | 2016 |
| A continuum model for tumour suppression AH Berger, AG Knudson, PP Pandolfi Nature 476 (7359), 163-169, 2011 | 636 | 2011 |
| Institutional implementation of clinical tumor profiling on an unselected cancer population LM Sholl, K Do, P Shivdasani, E Cerami, AM Dubuc, FC Kuo, EP Garcia, ... JCI insight 1 (19), 2016 | 378 | 2016 |
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 H Greulich, B Kaplan, P Mertins, TH Chen, KE Tanaka, CH Yun, X Zhang, ... Proceedings of the National Academy of Sciences 109 (36), 14476-14481, 2012 | 324 | 2012 |
| High-throughput phenotyping of lung cancer somatic mutations AH Berger, AN Brooks, X Wu, Y Shrestha, C Chouinard, F Piccioni, ... Cancer cell 30 (2), 214-228, 2016 | 215 | 2016 |
| Haplo‐insufficiency: a driving force in cancer AH Berger, PP Pandolfi The Journal of pathology 223 (2), 138-147, 2011 | 144 | 2011 |
| Identification of DOK genes as lung tumor suppressors AH Berger, M Niki, A Morotti, BS Taylor, ND Socci, A Viale, C Brennan, ... Nature genetics 42 (3), 216-223, 2010 | 134 | 2010 |
| Oncogenic RIT1 mutations in lung adenocarcinoma AH Berger, M Imielinski, F Duke, J Wala, N Kaplan, GX Shi, DA Andres, ... Oncogene 33 (35), 4418-4423, 2014 | 92 | 2014 |
| RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons JD Thomas, JT Polaski, Q Feng, EJ De Neef, ER Hoppe, MV McSharry, ... Nature genetics 52 (1), 84-94, 2020 | 81 | 2020 |
| BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP A Morotti, C Panuzzo, S Crivellaro, B Pergolizzi, U Familiari, AH Berger, ... Leukemia 28 (6), 1326-1333, 2014 | 81 | 2014 |
| Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome PCR Parrish, JD Thomas, AM Gabel, S Kamlapurkar, RK Bradley, ... Cell reports 36 (9), 2021 | 68 | 2021 |
| MET exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma X Lu, N Peled, J Greer, W Wu, P Choi, AH Berger, S Wong, KY Jen, Y Seo, ... Cancer research 77 (16), 4498-4505, 2017 | 65 | 2017 |
| Massively parallel phenotyping of coding variants in cancer with Perturb-seq O Ursu, JT Neal, E Shea, PI Thakore, L Jerby-Arnon, L Nguyen, D Dionne, ... Nature biotechnology 40 (6), 896-905, 2022 | 55 | 2022 |
| Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis A Lunardi, S Varmeh, M Chen, R Taulli, J Guarnerio, U Ala, N Seitzer, ... Cancer discovery 5 (5), 550-563, 2015 | 45 | 2015 |
| Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation H Gelman, JN Dines, J Berg, AH Berger, S Brnich, FM Hisama, RG James, ... Genome Medicine 11, 1-11, 2019 | 44 | 2019 |
